---
title: "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293133843.md"
description: "On July 17, 2026, San Carlos based Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) revealed the approval of granting inducement stock options on July 16, 2026. The options cover a total of 139,930 shares of the company's common stock and have been offered to seventeen fresh, non-executive employees. Iovance focuses on developing innovative polyclonal tumor infiltrating lymphocyte (\"TIL\") therapies for cancer patients."
datetime: "2026-07-19T21:31:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293133843.md)
  - [en](https://longbridge.com/en/news/293133843.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293133843.md)
generator: "portal-rs"
---

# Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

On July 17, 2026, San Carlos based Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) revealed the approval of granting inducement stock options on July 16, 2026. The options cover a total of 139,930 shares of the company's common stock and have been offered to seventeen fresh, non-executive employees. Iovance focuses on developing innovative polyclonal tumor infiltrating lymphocyte ("TIL") therapies for cancer patients.

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [IOVA: Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook](https://longbridge.com/en/news/298626037.md)
- [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md)
- [CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session](https://longbridge.com/en/news/298589195.md)
- [ALXO: Biomarker-driven CD47 and novel EGFR ADC programs show promise for hard-to-treat cancers](https://longbridge.com/en/news/298621322.md)
- [Nerve Repair and Regeneration Market worth $12.64 billion by 2031 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/298743114.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**